Table of Contents
Journal of Neurodegenerative Diseases
Volume 2017, Article ID 9427269, 7 pages
https://doi.org/10.1155/2017/9427269
Clinical Study

Clinical Analysis of Algerian Patients with Pompe Disease

1Service de Neurologie, Faculté de Médecine, Université Constantine 3, Constantine, Algeria
2Laboratoire de Biologie et de Génétique Moléculaire, Faculté de Médecine, Université Constantine 3, Constantine, Algeria
3Service de Pédiatrie, Faculté de Médecine, Université Constantine 3, Constantine, Algeria
4Laboratoire des Maladies Héréditaires du Métabolisme, Biochimie et Biologie Moléculaire, Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Bron, France
5Laboratoire de Biochimie, Faculté de Médecine, Université Constantine 3, Constantine, Algeria
6Service de Chirurgie Orthopédique, Faculté de Médecine, Université Constantine 3, Constantine, Algeria
7Service Médecine Physique et Réadaptation Fonctionnelle, Faculté de Médecine, Université Constantine 3, Constantine, Algeria
8Service de Réanimation Médicale, Faculté de Médecine, Université Constantine 3, Constantine, Algeria

Correspondence should be addressed to Y. Sifi; rf.oohay@animifis

Received 30 April 2016; Accepted 9 October 2016; Published 6 February 2017

Academic Editor: Brian Spencer

Copyright © 2017 Y. Sifi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Hirschhorn and A. J. J. Reuser, “Glycogen storage disease Type II: acid α-glucosidase (acid maltase) deficiency,” in The Metabolic and Molecular Bases of Inherited Disease, C. R. Scriver, A. Beaudet, W. Sly, and D. Valle, Eds., McGraw-Hill Global Education Holdings, 2001. View at Google Scholar
  2. A. G. Engel and R. Hirschhorn, “Acid maltase deficiency,” in Myology: Basic and Clinical, A. G. E. A. C. Franzini-Armstrong, Ed., vol. 1-2, p. 1937, McGraw-Hill, New York, NY, USA, 2nd edition, 1994. View at Google Scholar
  3. B. L. Thurberg, C. L. Maloney, C. Vaccaro et al., “Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease,” Laboratory Investigation, vol. 86, no. 12, pp. 1208–1220, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Fukuda, L. Ewan, M. Bauer et al., “Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease,” Annals of Neurology, vol. 59, no. 4, pp. 700–708, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. M. G. E. M. Ausems, J. Verbiest, M. M. P. Hermans et al., “Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling,” European Journal of Human Genetics, vol. 7, no. 6, pp. 713–716, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. C.-Y. Lin, B. Hwang, K.-J. Hsiao, and Y.-R. Jin, “Pompe's disease in Chinese and prenatal diagnosis by determination of α-glucosidase activity,” Journal of Inherited Metabolic Disease, vol. 10, no. 1, pp. 11–17, 1987. View at Publisher · View at Google Scholar · View at Scopus
  7. P. S. Kishnani, W.-L. Hwu, H. Mandel, M. Nicolino, F. Yong, and D. Corzo, “A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease,” Journal of Pediatrics, vol. 148, no. 5, pp. 671–676.e2, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. H. M. P. Van den Hout, W. Hop, O. P. Van Diggelen et al., “The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature,” Pediatrics, vol. 112, no. 2, pp. 332–340, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. M. L. C. Hagemans, L. P. F. Winkel, P. A. Van Doorn et al., “Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients,” Brain, vol. 128, part 3, pp. 671–677, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Pellegrini, P. Laforet, D. Orlikowski et al., “Respiratory insufficiency and limb muscle weakness in adults with Pompe's disease,” European Respiratory Journal, vol. 26, no. 6, pp. 1024–1031, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. A. T. van der Ploeg and A. J. Reuser, “Pompe's disease,” The Lancet, vol. 372, no. 9646, pp. 1342–1353, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. ACMG Work Group on Management of Pompe Disease, P. S. Kishnani, R. D. Steiner et al., “Pompe disease diagnosis and management guideline,” Genetics in Medicine, vol. 8, no. 5, pp. 267–288, 2006. View at Publisher · View at Google Scholar
  13. A. J. Reuser, M. A. Kroos, M. M. Hermans et al., “Glycogenosis type II (acid maltase deficiency),” Muscle & Nerve. Supplement, vol. 3, pp. S61–S69, 1995. View at Google Scholar
  14. A. L. E. Montalvo, B. Bembi, M. Donnarumma et al., “Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II,” Human Mutation, vol. 27, no. 10, pp. 999–1006, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. P. R. Joshi, D. Gläser, S. Schmidt et al., “Molecular diagnosis of German patients with late-onset glycogen storage disease type II,” Journal of Inherited Metabolic Disease, vol. 31, no. 2, pp. S261–S265, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. A. T. van der Ploeg, P. R. Clemens, D. Corzo et al., “A randomized study of alglucosidase alfa in late-onset Pompe's disease,” The New England Journal of Medicine, vol. 362, no. 15, pp. 1396–1406, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Regnery, C. Kornblum, F. Hanisch et al., “36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy,” Journal of Inherited Metabolic Disease, vol. 35, no. 5, pp. 837–845, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Angelini, C. Semplicini, S. Ravaglia et al., “Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years,” Journal of Neurology, vol. 259, no. 5, pp. 952–958, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Laforêt, K. Laloui, B. Granger et al., “The French Pompe registry. Baseline characteristics of a cohort of 126 patients with adult Pompe disease,” Revue Neurologique, vol. 169, no. 8-9, pp. 595–602, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. Pompe Disease Diagnostic Working Group, B. Winchester, D. Bali et al., “Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting,” Molecular Genetics and Metabolism, vol. 93, no. 3, pp. 275–281, 2008. View at Publisher · View at Google Scholar
  21. L. E. Case, A. A. Beckemeyer, and P. S. Kishnani, “Infantile Pompe disease on ERT-Update on clinical presentation, musculoskeletal management, and exercise considerations,” American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, vol. 160, no. 1, pp. 69–79, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Amalfitano, A. R. Bengur, R. P. Morse et al., “Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial,” Genetics in Medicine, vol. 3, no. 2, pp. 132–138, 2001. View at Google Scholar · View at Scopus
  23. P. S. Kishnani, M. Nicolino, T. Voit et al., “Chinese hamster ovary cell-derived recombinant human acid α-glucosidase in infantile-onset Pompe disease,” Journal of Pediatrics, vol. 149, no. 1, pp. 89–97, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. P. S. Kishnani, D. Corzo, M. Nicolino et al., “Recombinant human acid α-glucosidase: major clinical benefits in infantile-onset Pompe disease,” Neurology, vol. 68, no. 2, pp. 99–109, 2007. View at Publisher · View at Google Scholar
  25. M. Nicolino, B. Byrne, J. E. Wraith et al., “Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease,” Genetics in Medicine, vol. 11, no. 3, pp. 210–219, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. M. G. E. M. Ausems, P. Lochman, O. P. Van Diggelen, H. K. Ploos Van Amstel, A. J. J. Reuser, and J. H. J. Wokke, “A diagnostic protocol for adult-onset glycogen storage disease type II,” Neurology, vol. 52, no. 4, pp. 851–853, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Fu, W. Qiu, Y. Yu et al., “Clinical and molecular genetic study of infantile-onset Pompe disease in Chinese patients: identification of 6 novel mutations,” Gene, vol. 535, no. 1, pp. 53–59, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. L. P. F. Winkel, J. M. P. Van Den Hout, J. H. J. Kamphoven et al., “Enzyme replacement therapy in late-onset pompe's disease: a three-year follow-up,” Annals of Neurology, vol. 55, no. 4, pp. 495–502, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Jegadeeswari, V. Amuthan, R. A. Janarthanan, S. Murugan, and S. Balasubramanian, “Two cases of Pompe's disease: case report and review of literature,” Indian Heart Journal, vol. 64, no. 2, pp. 214–216, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. P. S. Kishnani, S. BurnsWechsler, and J. S. Li, “Enzyme-deficiency metabolic cardiomyopathies and the role of enzyme replacement therapy,” Progress in Pediatric Cardiology, vol. 23, no. 1-2, pp. 39–48, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. O. I. I. Soliman, N. A. M. E. Van Der Beek, P. A. Van Doorn et al., “Cardiac involvement in adults with Pompe disease,” Journal of Internal Medicine, vol. 264, no. 4, pp. 333–339, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. U. Raju, S. C. Shaw, K. S. Rana, M. Sharma, and H. R. Ramamurthy, “Pompe's disease in childhood: a metabolic myopathy,” Medical Journal Armed Forces India, vol. 66, no. 1, pp. 32–36, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. L. E. Case and P. S. Kishnani, “Physical therapy management of Pompe disease,” Genetics in Medicine, vol. 8, no. 5, pp. 318–327, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. L. P. F. Winkel, M. L. C. Hagemans, P. A. Van Doorn et al., “The natural course of non-classic Pompe's disease; a review of 225 published cases,” Journal of Neurology, vol. 252, no. 8, pp. 875–884, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. N. A. M. E. van der Beek, C. I. van Capelle, K. I. van der Velden-van Etten et al., “Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease,” Molecular Genetics and Metabolism, vol. 104, no. 1-2, pp. 129–136, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Burghaus, W. Liu, E. Neuen-Jacob, K. Gempel, and W. Haupt, “Selective respiratory failure as a rare first symptom of Pompe's disease,” Nervenarzt, vol. 77, no. 2, pp. 181–186, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. W. Müller-Felber, R. Horvath, K. Gempel et al., “Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients,” Neuromuscular Disorders, vol. 17, no. 9-10, pp. 698–706, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. E. J. Cupler, K. I. Berger, R. T. Leshner et al., “Consensus treatment recommendations for late-onset pompe disease,” Muscle & Nerve, vol. 45, no. 3, pp. 319–333, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. N. Preisler, Z. Lukacs, L. Vinge et al., “Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies,” Molecular Genetics and Metabolism, vol. 110, no. 3, pp. 287–289, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Sacconi, J. D. Bocquet, S. Chanalet, V. Tanant, L. Salviati, and C. Desnuelle, “Abnormalities of cerebral arteries are frequent in patients with late-onset Pompe disease,” Journal of Neurology, vol. 257, no. 10, pp. 1730–1733, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. U. Mellies, F. Stehling, C. Dohna-Schwake, R. Ragette, H. Teschler, and T. Voit, “Respiratory failure in Pompe disease: treatment with noninvasive ventilation,” Neurology, vol. 64, no. 8, pp. 1465–1467, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. U. K. Dhand and R. Dhand, “Sleep disorders in neuromuscular diseases,” Current Opinion in Pulmonary Medicine, vol. 12, no. 6, pp. 402–408, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. H. Zhang, H. Kallwass, S. P. Young et al., “Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid α-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease,” Genetics in Medicine, vol. 8, no. 5, pp. 302–306, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. M. T. Di Fiore, R. Manfredi, L. Marri, A. Zucchini, L. Azzaroli, and G. Manfredi, “Elevation of transaminases as an early sign of late-onset glycogenosis type II,” European Journal of Pediatrics, vol. 152, no. 9, p. 784, 1993. View at Publisher · View at Google Scholar · View at Scopus
  45. T.-M. Ko, W.-L. Hwu, Y.-W. Lin et al., “Molecular genetic study of Pompe disease in Chinese patients in Taiwan,” Human Mutation, vol. 13, no. 5, pp. 380–384, 1999. View at Publisher · View at Google Scholar · View at Scopus
  46. L. H. Hoefsloot, M. Hoogeveen-Westerveld, M. A. Kroos, J. van Beeumen, A. J. Reuser, and B. A. Oostra, “Primary structure and processing of lysosomal alpha-glucosidase; homology with the intestinal sucrase-isomaltase complex,” EMBO Journal, vol. 7, no. 6, pp. 1697–1704, 1988. View at Google Scholar · View at Scopus
  47. F. Martiniuk, M. Mehler, A. Pellicer et al., “Isolation of a cDNA for human acid α-glucosidase and detection of genetic heterogeneity for mRNA in three α-glucosidase-deficient patients,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 24, pp. 9641–9644, 1986. View at Publisher · View at Google Scholar · View at Scopus
  48. F. Martiniuk, M. Mehler, S. Tzall, G. Meredith, and R. Hirschhorn, “Sequence of the cDNA and 5′-flanking region for human acid α-glucosidase, detection of an intron in the 5′ untranslated leader sequence, definition of 18-bp polymorphisms, and differences with previous cDNA and amino acid sequences,” DNA and Cell Biology, vol. 9, no. 2, pp. 85–94, 1990. View at Publisher · View at Google Scholar · View at Scopus
  49. L. Klinge, V. Straub, U. Neudorf, and T. Voit, “Enzyme replacement therapy in classical infantile Pompe disease: results of a ten-month follow-up study,” Neuropediatrics, vol. 36, no. 1, pp. 6–11, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Rohrbach and J. T. R. Clarke, “Treatment of lysosomal storage disorders: progress with enzyme replacement therapy,” Drugs, vol. 67, no. 18, pp. 2697–2716, 2007. View at Publisher · View at Google Scholar · View at Scopus